跳至主要内容
临床试验/NCT03569930
NCT03569930Unknown4 期

Irritation and Anal Bleeding in Patients Affected by Hemorrhoids: Comparative Evaluation of Three Different Treatments.

University of Roma La Sapienza1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2018年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
105
试验地点
1
主要终点
delta of time necessary for the disappearance of bleeding

研究概览

简要总结

Haemorrhoidal disease is an increasingly frequent benign condition, able to negatively affect the quality of working and relationship life in affected individuals.The primary objective of the study is the comparative assessment of the time necessary for the disappearance of bleeding comparatively in the three different therapies (controls, ProtFlav and ProtCent) to identify, if any, the most effective treatment, in terms of time reduction for the disappearance of bleeding in subjects affected by haemorrhoidal disease.

Patients enrolled will be randomized into 3 groups:

  1. the control group in which the patients will be subjected to the standard therapeutic care (diet rich in water and vegetable fibers, hygienic),
  2. interventional group "ProtFlav": in which oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
  3. interventional group "ProtCent": in which an anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care

详细描述

Haemorrhoidal disease is an increasingly frequent benign condition, able to negatively affect the quality of working and relationship life in affected individuals.The primary objective of the study is the comparative assessment of the time necessary for the disappearance of bleeding comparatively in the three different therapies (controls, ProtFlav and ProtCent) to identify, if any, the most effective treatment, in terms of time reduction for the disappearance of bleeding in subjects affected by haemorrhoidal disease.

Secondary objectives are the evaluation of the longitudinal trend in time of anal irritation measured with the VAS scale and the study of the longitudinal performance of BMI (Body Mass Index).

The patients enrolled in the protocol will be randomized into 3 groups: the control group in which the patients will be subjected to a diet rich in water and vegetable fibers, hygienic care and anal dilator according to the traditional standardized scheme. The two experimental groups will be subjected to the same standard therapeutic scheme (diet rich in water and vegetable fibers, hygienic) of the controls, in addition to which will be added to oral supplements (group "ProtFlav") and local application as an anal cream (group "ProtCent"). Of the patients in the interventional groups, half will take flavonoid-based supplements (ProtFlav) and the other half will take supplements and anal cream based on Centella asiatica (ProtCent), as better specified below. All patients will be followed for a period of 8 weeks or otherwise until recovery (disappearance of irritation and stop bleeding).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female affected by acute haemorrhoidal disease
  • Collaborating patients, able to understand

排除标准

  • Women who are pregnant or have been breastfeeding;
  • Previous colorectal surgery;
  • Anal stenosis;
  • Treatment (topical or systemic) with decongestants, diuretics, steroidal anti-inflammatory drugs or NSAIDs, antipyretics, antibiotics or antivirals for other reasons;
  • Psychiatric and / or toxic employees;
  • Age in completed years, less than 18 and over 85;
  • If the patient's personal clinical record does not have at least two controls, it is excluded from the clinical study;
  • Refusal to participate in the study.

研究组 & 干预措施

Standard

Experimental

standard of care (diet rich in water and vegetable fibers, hygienic)

干预措施: standard of care (Behavioral)

ProtFlav

Experimental

oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care

干预措施: flavonoid-based supplements (Drug)

ProtCent

Experimental

anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care

干预措施: Centella Complex (Drug)

结局指标

主要结局

delta of time necessary for the disappearance of bleeding

时间窗: 3 months

comparative assessment of the time necessary for the disappearance of bleeding

次要结局

  • delta of BMI (Body Mass Index).(3 months)
  • delta of Visual Analog Scale for Pain (VAS Pain)(3 months)

研究者

发起方
University of Roma La Sapienza
申办方类型
Other
责任方
Principal Investigator
主要研究者

Massimo Chiaretti

Clinical Professor

University of Roma La Sapienza

研究点 (1)

Loading locations...

相似试验